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chart-review study of PsA patients was conducted among physicians in hospitals/
private practices to collect de-identified data on patients recently treated with a 
biologic as part of usual care. Physicians from UK/Germany/France/Italy/Spain (5EU) 
were screened for practice-duration and patient-volume and recruited from a large 
panel to be geographically representative in each country. Eligible patient charts (> 2) 
were randomly selected from a sample of prospective patients visiting each center/
practice during the screening period. Physicians abstracted patient diagnosis, treat-
ment patterns/dynamics and patient symptomatology/disease status. Results: 
Between Jan2011-Dec2012, 454 PsA patients (mean age:48.8yrs;female:49.6%) on 
2nd-line biologic after 1st-line anti-TNF failure were identified. Mean time-to-1st-
line anti-TNF from diagnosis was 51.6months; mean time on 1st-line anti-TNF was 
18.3months (patients < 6/7-12/13-24/> 24months:33%/21%/19%/27%). Top-3 1st line 
anti-TNFs observed were: etanercept(38%), adalimumab(32%), and infliximab(27%). 
The top-5 reasons for 1st-line anti-TNF discontinuation were ‘long-term efficacy 
failure’, ‘disease worsened’, ‘side-effects not tolerated’, ‘insufficient-improve-
ment’, and ‘initial failure of efficacy’. Mean time on current 2nd-line biologic was 
18.5months (patients < 6/7-12/13-24/> 24months:28%/21%/25%/27%). Current 2nd-
line biologics (top-5) included: adalimumab(39%)/etanercept(31%)/infliximab(14%)/
golimumab(11%)/abatacept(2%). Top-5 reasons for choice of 2nd-line biologic were 
‘mechanism of action’, ‘prevention of structural damage’, ‘improve signs/symp-
toms’, ‘disease worsened’, ‘positive personal experience’. Key lab measures docu-
mented were: ESR-21.7mm/h and CRP-8.3mg/dl. Among patients with available 
data, current HAQ was 1.1, Swollen Joint Count was 1.9 and Tender Joint Count 
was 3.4. Current disease severity per physician judgment (mild:moderate:severe) 
were: 48%:47%:5%. Current disease severity (mild:moderate:severe) by time on 1stline 
anti-TNF biologic (< 6/7-12/13-24/> 24months) were 47%:48%:5% / 55%:42%:3% / 
49%:48%:4% / 44%:49%:7% respectively. ConClusions: Among PsA pts on their 2nd 
biologic who experienced anti-TNF failure, 54% discontinued their 1st line anti-TNF 
regimen within 12months of initiation and continue to have considerable disease 
burden despite current 2nd line biologic.
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objeCtives: Until 2010 the cost of biological treatments in Rheumatoid Arthritis 
(RA) was increased annually by 15% in our hospital. In 1stJanuary 2011, a Hospital 
Commission and Protocol of Biological Therapies were created to improve the 
cost-effectiveness usage of biological drugs in RA. To evaluate the economic impact 
associated with a biological therapy prioritization Protocol for RA patients in the 
Hospital of Sagunto. Methods: Observational, ambispective study comparing 
the associated cost of biotreated RA patients pre-protocol (2009-2010) versus 
post-protocol periods (2011-2012). Inclusion criteria: RA patients treated with 
Abatacept (ABA) Adalimumab (ADA), Etanercept (ETN) or Infliximab (IFX) for at 
least 6 months during the study period (2009-2012). ETN was selected as 1st line 
therapy because our successful experience of ETN 25 mg/weekly in certain RA 
patients, its subcutaneous administration and lowest theoretical cost per patient 
in Spain. Cost savings and economic impact were calculated using Spanish offi-
cial prices. Results: In the pre-protocol period (2009-2010), total expenses were 
increased by 110,000€ , up to 1,761,000€ in 2010 (11,362€ pat/year). After protocol 
implementation, total expenses decreased by 53,676€ on the 2010-2011 period, and 
149,200€ on the 2011-2012 period. On the 2010-2011 period the cost of biological 
therapy per patient-year decreased 355€ (11,007€ pat/year) and additional 653€ (up 
to 10,354€ pat/year) by 2012, with a cumulative effect of the protocol implementa-
tion of 1,008€ per patient-year. In the pre-protocol period, the annual cost/patient 
was 10.812€ with ETN, 10.942€ with IFX, 12.961€ with ADA and 12.739€ with ABA. 
By 1st Jan 2013, the annual cost per patient was 9,469€ with ETN, 10,579€ with 
IFX, 11,117€ with ADA and 13,540€ with ABA. ConClusions: The creation of our 
Commission of Biological Therapies is key to rational management of RA patients 
and optimization of resources, allowing us to save 200,000€ after 2-year efficiency 
protocol implementation.
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objeCtives: To describe the current medical management of Rheumatoid 
Arthritis (RA) patients in routine practice in a national representative sample of 
patients, focusing on biological agents (BA) uptake. Methods: The EGB database 
is a 1/97 representative sample of the national claims database covering the whole 
French population. RA patients were identified as adults (age > 18) benefiting from 
full coverage (“ALD” eligibility criteria) for RA (ICD-10 codes M05-06) on January 1, 
2009. Patients treated by BA were defined as RA patients with at least one claim 
for at least one BA over the period. BA-naïve treated patients were identified by 
the absence of a BA claim during the first 3 months of the study period, followed 
by at least one BA claim. Results: Over the 3-year period, 236 patients had a BA 
reimbursed and 5,336 deliveries by pharmacists were observed. The proportion 
of BA users, either alone or in combination, was 14.0% in 2009, and 70 patients 
(32.7%) used a BA in combination with methotrexate. Among patients treated by 
BA, 85.2% used at least one TNF inhibitor during the study period. Etanercept had 
the highest delivery record (58.1%), followed by adalimumab (28.8%) and infliximab 
(15.3%). Among the whole group of patients treated by BA, 13.6% were delivered 
rituximab at least once. Over the period, a proportion of 73.3% of patients had one 
BA agent only, 19.1% experienced one switch and 7.6% had two or more switches. 
differed between those in remission vs. those who were not: Tender Joint Count: 
2.3-vs-6.1, Swollen Joint Count: 1.2-vs-4.2, 100mm VAS score: 18.6-vs-42.8, HAQ: 
0.7-vs-1.6 and DAS28: 2.6-vs-4.4. ConClusions: More than half of the patients 
were not in remission in this diverse cohort of RA patients in 5-EU and they experi-
enced disproportionate level of disease burden. As the line of treatment increased, 
proportion of individuals achieving remission decreased. These observed patterns 
warrant further scrutiny to determine the best practices and improve remission 
rates, thereby alleviating patient burden.
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objeCtives: To assess the clinical characteristics of patients with RA receiving their 
first biologic in EU and the US. Methods: A multi-country medical chart-review 
study of RA patients was conducted among physicians (majority: rheumatologists) 
in hospitals and private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians from UK, Germany, 
France, Italy and Spain (5EU) and the US were screened for duration of practice and 
patient volume and recruited from a large panel to be geographically representa-
tive in each country. Eligible RA patient charts (> 5) were randomly selected from 
a sample of prospective patients visiting each center/practice during the screen-
ing period. Physicians abstracted patient diagnosis, treatment patterns/dynamics 
and patient symptomatology/disease status. Results: In 4Q2012, 434 physicians 
(5EU:337; US:97) abstracted 2085 (5EU:1534; US:551) eligible RA patient charts; cur-
rent biologic patterns (5EU/US) were: 1st line (78%/69%), 2nd line (16%/21%) & 3rd+ 
line (6%/11%). 1577 (5EU:1199; US: 378) patients were on their first biologic. Mean 
age – 5EU:50.8yrs, US:52.8yrs; female – 5EU:73%; US:73%. Mean time-to-1st biologic 
(5EU/US) from diagnosis was 40/28 months; mean time on current 1st biologic (5EU/
US) was 24/34 months. Top-3 biologic treatments observed were – etanercept (5EU/
US:37%/42%), adalimumab (5EU/US:34%/32%), and infliximab (5EU/US:8%/10%). 
The top-5 reasons for biologic treatment initiation were the same across 5EU/US 
(‘mechanism of action’, ‘improve signs/symptoms’, ‘prevent structural damage’, 
‘positive personal experience’, ‘inhibits disease progression’). Key lab measures 
documented were (5EU/US): ESR (22.7/24.2mm/h) and CRP (10.9/2.5mg/dl). Current 
disease severity per physician judgment (mild:moderate:severe) were: 5EU-
57%:37%:6%, US-67%:29%:3%. Among patients with available data, current HAQ 
(5EU:1.2/US:0.7), DAS28 (5EU:3.4/US:2.5), 100mmVAS (5EU:3.5/US:2.3), Swollen Joint 
Count (SWC) (5EU:2.6/US:2.0) and Tender Joint Count (TJC) (5EU:3.9/US:2.8) differed 
within between 5EU and US. ConClusions: Among RA patients receiving their 
first biologic, disease severity differed between 5EU and US, with patients in 5EU 
with relatively higher burden.
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objeCtives: To evaluate physician assessment of patient eligibility and even-
tual use of biologics in RA, AS, and PsA in the US. Methods: A multi-country 
cross-sectional survey of physicians (primarily rheumatologists) was conducted 
in the US. Physicians were screened for biologic patient volume (> 2RA biologic 
patients/week, > 5AS biologic patients/month, > 5PsA biologic patients/month) 
and recruited from a large physician-panel to be geographically representative. 
Practice characteristics, patient-volume, physician perceptions and practice pat-
terns were assessed; physicians’ target patient population was grouped into 2 
categories, based on physician input: Group1 – patients perceived to be eligible 
for biologics, Group2 – patients who ended up receiving biologics within Group1. 
Summary statistics across the US are reported. Results: In 4Q2012, 97 physicians 
participated in the study. Mean age: 47.6yrs; female: 30%. Main practice: private 
office (non-hospital):46%. Patient volume per physician was: total-1904, RA-419, 
AS-82, PsA-145. Average frequency of patient encounters were (RA/AS/PsA; weeks): 
11/12/11. Physician judgment of patient disease severity were (average across their 
patients): RA – mild:28%/moderate:47%/severe:25%, AS – mild:31%/moderate:43%/
severe:26% and PsA – mild:30%/moderate:44%/severe:27%. Physician assess-
ment of patient eligibility and use of biologics were: within RA-mild-patients – 
Group1:21%/Group2:14%, within RA-moderate-patients – Group1:63%/Group2:51%, 
within RA-severe-patients – Group1:81%/Group2:70%; within AS-mild-patients – 
Group1:32%/Group2:24%, within AS-moderate-patients – Group1:66%/Group2:55%, 
within AS-severe-patients – Group1:79%/Group2:69%; within PsA-mild-patients – 
Group1:30%/Group2:23%, within PsA-moderate-patients – Group1:66%/Group2:55%, 
within PsA-severe-patients – Group1:81%/Group2:71%. Among the top-3 biologic 
treatments used, etanercept, adalimumab, and infliximab were observed throughout 
RA, AS and PsA. ConClusions: Across the markets, between 30-45% of biologic 
eligible patients (per physician perception) within moderate/severe disease sever-
ity groups did not end up receiving a biologic therapy across RA/AS/PsA cohorts. 
Reasons behind these patterns and the impact on subsequent patient outcomes 
warrant further scrutiny.
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objeCtives: To assess treatment patterns and disease burden among PsA patients 
on 2nd-line biologics after 1st-line anti-TNF failure. Methods: A multi-country 
